Multiple Myeloma Articles

Lonial Discusses Dramatic Progress in Multiple Myeloma
Sagar Lonial, MD, discusses recent advances that have revolutionized the treatment of patients with multiple myeloma.
Novel Study of Next-Generation BCMA-Targeted CAR-Modified T Cells for Multiple Myeloma Opens at MSK
Ola Landgren, MD, PhD, discusses a new clinical trial at Memorial Sloan Kettering examining a novel myeloma-directed CAR T-cell therapy developed by researchers at the cancer center.
Denosumab Effective in Delaying SREs in Myeloma
Denosumab (Xgeva) demonstrated noninferiority to zoledronic acid (Zometa) at delaying the time to the first skeletal-related event in patients with multiple myeloma, according to the full results of the phase III 482 study presented at the 16th International Myeloma Workshop in New Delhi.
Carfilzomib Improves Survival in Relapsed Multiple Myeloma
Carfilzomib (Kyprolis) plus dexamethasone improved overall survival by 21% versus dexamethasone plus bortezomib (Velcade) in patients with relapsed or refractory multiple myeloma, according to findings from the phase III ENDEAVOR trial.
Outcomes Have Improved Over Time in Myeloma Patients Relapsing Early After ASCT
Rates of early relapse post-autologous stem cell transplant in patients with relapsing multiple myeloma have not changed over time, but post-relapse survival among early relapsers has improved for patients transplanted after 2005 and for those relapsing since 2008.
Carfilzomib Maintenance Improves Response Following Transplant in Relapsed Multiple Myeloma
According to data from a phase I/II clinical trial, carfilzomib can be safely combined with melphalan in a conditioning regimen prior to autologous hematopoietic cell transplantation in patients with relapsed multiple myeloma.
Daratumumab Triplets Recommended for EU Approval in Myeloma
The EMA’s Committee for Medicinal Products for Human Use has recommended approval of daratumumab (Darzalex) in combination with lenalidomide (Revlimid) and dexamethasone or bortezomib (Velcade) and dexamethasone for patients with relapsed multiple myeloma following at least 1 prior therapy.
EC Approves Maintenance Lenalidomide for Myeloma
The European Commission has expanded the indication for lenalidomide (Revlimid) to include use as a maintenance therapy for patients with multiple myeloma following autologous hematopoietic stem cell transplant.
FDA Approves Maintenance Lenalidomide for Myeloma
The FDA has approved lenalidomide (Revlimid) as a maintenance therapy for patients with multiple myeloma following autologous hematopoietic stem cell transplant.
Expert Highlights Immunotherapy Advances in Myeloma
Eric Smith, MD, PhD, discusses recently reported phase II data combining elotuzumab (Empliciti) with lenalidomide (Revlimid) and dexamethasone.
Publication Bottom Border
Border Publication